Cigna Denied Your Genetic Testing? How to Appeal

Why Cigna Denies Genetic Testing Claims

Genetic testing has become an essential component of modern medicine, informing cancer risk assessment, treatment selection, carrier screening, and diagnosis of rare diseases. Tests for BRCA1/BRCA2 mutations, Lynch syndrome, hereditary cardiac conditions, pharmacogenomic profiles, and whole exome sequencing are routinely ordered by specialists to guide clinical decisions. Despite the clinical value, Cigna denies genetic testing claims at high rates, leaving patients unable to access the genomic information their physicians need to guide treatment.

medical necessity criteria not met. Cigna maintains detailed clinical coverage policies for genetic testing that specify which tests are covered, for which indications, and which patients qualify. Cigna typically requires a specific personal or family history pattern before authorizing hereditary cancer testing, such as a diagnosis of breast cancer before age 50, multiple family members with the same cancer, or a known familial mutation. If the ordering physician's documentation does not clearly match Cigna's criteria, the test is denied.

Experimental or investigational classification. Cigna classifies many newer genetic tests as experimental or investigational, meaning the insurer has determined there is insufficient evidence that the test results will change clinical management. This classification is applied to multigene panels that include genes Cigna considers investigational, whole genome sequencing, certain pharmacogenomic panels, and genetic tests for conditions where Cigna asserts clinical utility has not been established.

Panel testing versus single-gene testing. Cigna may approve single-gene testing (for example, BRCA1/BRCA2 alone) but deny multigene panels that test for multiple hereditary cancer genes simultaneously. Cigna argues that the additional genes on the panel do not meet medical necessity criteria, even when the ordering physician has clinical reasons to test for multiple genes based on the patient's presentation.

Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization not obtained. Cigna requires prior authorization for most genetic tests. If the test was performed without obtaining prior authorization, Cigna will deny the claim regardless of the results or clinical utility.

Preferred laboratory requirements. Cigna may require that genetic testing be performed at a preferred or contracted laboratory and deny claims when the test is performed at an out-of-network or non-preferred lab. This can be problematic when the ordering physician sends samples to a specific laboratory because it is the only lab that performs a particular test or uses a clinically validated methodology.

Duplicate testing denials. If prior genetic testing has been performed, Cigna may deny additional testing as duplicative, even when the new test covers different genes, uses updated methodology, or is clinically necessary to guide a different treatment decision.

Common Denial Codes and Reasons

• Not medically necessary -- Cigna's reviewer determined the genetic test is not clinically justified
• Experimental or investigational -- Cigna classified the test as unproven
• Prior authorization not obtained -- The test was performed without required authorization
• Does not meet clinical criteria -- The patient's personal or family history does not match Cigna's coverage criteria
• Non-preferred laboratory -- The test was performed at a laboratory outside Cigna's preferred network
• Duplicate testing -- Prior genetic testing was performed, and additional testing is deemed unnecessary
• Panel exceeds coverage -- Cigna covers single-gene testing but not the multigene panel ordered

Your Legal Rights

ACA Preventive Services Mandate

The ACA requires coverage of certain genetic tests as preventive services with no cost-sharing. The U.S. Preventive Services Task Force (USPSTF) recommends BRCA-related genetic counseling and testing for women with a personal or family history pattern suggesting hereditary breast/ovarian cancer. Under the ACA, this testing must be covered without copay, coinsurance, or deductible when ordered based on a USPSTF-qualifying risk assessment. If Cigna denied BRCA testing for a patient who meets USPSTF criteria, this is a direct violation of the ACA preventive services mandate.

ACMG and NCCN Clinical Guidelines

The American College of Medical Genetics and Genomics (ACMG) and the NCCN publish clinical guidelines for genetic testing indications. NCCN guidelines for hereditary cancer testing are widely recognized as the standard of care. When genetic testing is recommended by NCCN guidelines for a patient's specific clinical scenario, this is strong evidence of medical necessity.

Genetic Information Nondiscrimination Act (GINA)

While GINA does not require coverage of genetic testing, it prohibits health insurers from using genetic information to deny coverage or increase premiums. This protection ensures that pursuing genetic testing cannot be used against you in future coverage decisions.

erisa-protections">ERISA Protections

For employer-sponsored plans, ERISA guarantees the right to appeal, access to the complete claims file, and a written explanation of the denial. ERISA requires Cigna to provide the specific clinical policy applied and the qualifications of the reviewer who denied the test.

State Genetic Testing Mandates

Several states have enacted laws requiring insurance coverage for specific genetic tests, particularly BRCA testing and other hereditary cancer testing. Some states also mandate coverage of pharmacogenomic testing when prescribed to guide medication selection. Check your state's specific genetic testing coverage requirements.

Step-by-Step Appeal Instructions

Step 1: Request the Complete Claims File

Contact Cigna and request the full claims file, including the specific clinical coverage policy applied (Cigna's genetic testing medical policy), the reviewer's credentials, and the specific criteria the reviewer determined were not met.

Step 2: Obtain Detailed Clinical Documentation

Your ordering physician (oncologist, geneticist, genetic counselor, or specialist) should provide:

• Complete personal medical history relevant to the testing indication (cancer diagnosis with histology and staging, family history of cancer or genetic condition across at least three generations)
• A detailed family history pedigree documenting affected relatives, cancer types, ages at diagnosis, and known genetic mutations in the family
• The specific genetic test ordered with CPT codes and the clinical question it is intended to answer
• How the test results will change clinical management (surgical decisions, surveillance protocols, chemoprevention, treatment selection, family screening)
• Citations to NCCN, ACMG, or other relevant clinical guidelines recommending testing for the patient's specific scenario
• If a multigene panel is at issue: clinical rationale for testing multiple genes rather than a single gene, including overlap in cancer phenotypes and the efficiency of panel testing
• If pharmacogenomic testing: the specific medication decision the test will inform and evidence that pharmacogenomic results improve outcomes for that medication
• If the test was classified as experimental: citations to published peer-reviewed studies demonstrating clinical validity and clinical utility

Step 3: Verify ACA Preventive Services Coverage

If the genetic test is BRCA-related and the patient meets USPSTF risk criteria, verify that the denial does not violate the ACA preventive services mandate. If it does, cite this violation specifically in your appeal -- the test must be covered with zero cost-sharing.

Step 4: File the Internal Appeal

Submit your appeal within 180 days. Address the specific denial reason:

• If denied for medical necessity criteria: Present the clinical documentation demonstrating the patient meets the criteria in Cigna's policy, or argue that Cigna's criteria are more restrictive than NCCN/ACMG guidelines and the generally accepted standard of care
• If denied as experimental: Present published evidence of clinical validity and utility, FDA clearance or approval of the test if applicable, and adoption by major medical organizations
• If denied for multigene panel: Argue that panel testing is more efficient and cost-effective than sequential single-gene testing, and is recommended by NCCN for patients where multiple genes are clinically relevant
• If denied for ACA preventive testing: Cite the USPSTF recommendation and the ACA mandate for zero cost-sharing preventive services

Request an expedited appeal if the test results are needed to guide an urgent treatment decision (cancer treatment planning, prenatal diagnosis).

Step 5: Request a Peer-to-Peer Review

Your ordering physician can request a peer-to-peer review with Cigna's medical director to explain the clinical context and how the test results will directly impact patient management.

Step 6: Pursue External Independent Review: Complete Guide" class="auto-link">External Review

If Cigna upholds the denial, file for external review. An independent genetics or oncology specialist will evaluate the clinical necessity. External review is free and binding on Cigna.

Step 7: File Regulatory Complaints

File a complaint with your state Department of Insurance through the NAIC directory. If the denial involves BRCA testing that should be covered as a preventive service under the ACA, specifically cite this in your regulatory complaint.

Common Mistakes to Avoid

Not including a detailed family history pedigree. Genetic testing coverage criteria are heavily based on personal and family history. A vague family history is insufficient -- provide a detailed three-generation pedigree with cancer types, ages at diagnosis, and known mutations.

Not explaining clinical utility. Cigna wants to know how the test results will change clinical management. A test ordered "for informational purposes" is easier to deny than a test ordered to guide a specific treatment decision.

Not checking whether the test qualifies as ACA preventive care. BRCA testing for women meeting USPSTF risk criteria must be covered with no cost-sharing. Many patients and providers do not realize this and accept the denial.

Not challenging the experimental classification. Just because Cigna labels a test experimental does not make it so. If the test is endorsed by NCCN, ACMG, or other major medical organizations, challenge the classification with published evidence.

Using a non-preferred laboratory without clinical justification. If Cigna's preferred lab performs the same test, using the preferred lab avoids a preventable denial. If there is a clinical reason to use a different lab, document it.

Draft Your Cigna Genetic Testing Appeal with ClaimBack

Fighting a genetic testing denial requires matching your clinical scenario to Cigna's coverage criteria, citing NCCN and ACMG guidelines, and demonstrating clinical utility. ClaimBack at claimback.app generates professional appeal letters tailored to your specific Cigna genetic testing denial, incorporating the family history documentation, guideline citations, and regulatory arguments that give you the best chance of getting your genetic test covered.

Conclusion

A Cigna genetic testing denial does not have to prevent you from obtaining critical genomic information. With a detailed family history, strong clinical utility documentation, NCCN/ACMG guideline citations, and a systematic appeal strategy, genetic testing denials are frequently overturned. Start your appeal today with ClaimBack at claimback.app.

Related Reading

• UnitedHealthcare Denied Genetic Testing? How to Appeal
• Cancer Genetic Testing Insurance Denied? How to Appeal BRCA, Lynch Syndrome, and More
• Genetic Testing Insurance Claim Denied? How to Appeal
• Insurance Denied Genetic Testing? Your Appeal Rights
• Cigna Denied Your ABA Therapy For Autism? How to Appeal